15 results on '"Adah, Dickson"'
Search Results
2. Subsequent malaria enhances virus-specific T cell immunity in SIV-infected Chinese rhesus macaques
3. Plasmodium infection inhibits triple negative 4T1 breast cancer potentially through induction of CD8+ T cell-mediated antitumor responses in mice
4. The mechanisms of action of Plasmodium infection against cancer
5. Plasmodium infection inhibits the expansion and activation of MDSCs and Tregs in the tumor microenvironment in a murine Lewis lung cancer model
6. Soluble programmed death ligand‐1‐induced immunosuppressive effects on chimeric antigen receptor‐natural killer cells targeting Glypican‐3 in hepatocellular carcinoma.
7. Prodrug‐Loaded Zirconium Carbide Nanosheets as a Novel Biophotonic Nanoplatform for Effective Treatment of Cancer.
8. A novel tumour suppressor lncRNA F630028O10Rik inhibits lung cancer angiogenesis by regulating miR‐223‐3p.
9. 4‑Aryl Pyrrolidines as Novel Orally Efficacious Antimalarial Agents. Part 2: 2‑Aryl‑N‑(4-arylpyrrolidin-3-yl)acetamides.
10. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
11. The complement receptor C5aR2 promotes protein kinase R expression and contributes to NLRP3 inflammasome activation and HMGB1 release from macrophages.
12. Plasmodium immunotherapy combined with gemcitabine has a synergistic inhibitory effect on tumor growth and metastasis in murine Lewis lung cancer models.
13. Experimental Treatment of SIV-Infected Macaques via Autograft of CCR5 -Disrupted Hematopoietic Stem and Progenitor Cells.
14. The complement receptor C5aR2 promotes protein kinase R expression and contributes to NLRP3 inflammasome activation and HMGB1 release from macrophages.
15. Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.